SAN DIEGO–(BUSINESS WIRE)–Boundless Bio, a company interrogating and targeting ecDNA in aggressive cancers, announced the completion of a $46.4M Series A financing.
SAN DIEGO–(BUSINESS WIRE)–Boundless Bio, a company interrogating and targeting ecDNA in aggressive cancers, announced the completion of a $46.4M Series A financing.
Copyright © 2021 | MH Magazine WordPress Theme by MH Themes